Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Associations of lifetime traumatic experience with dysfunctional eating patterns and postsurgery weight loss in adults with obesity: A retrospective study.

Ruffault A, Vaugeois F, Barsamian C, Lurbe I Puerto K, Le Quentrec-Creven G, Flahault C, Naudé AJ, Ferrand M, Rives-Lange C, Czernichow S, Carette C.

Stress Health. 2018 Aug;34(3):446-456. doi: 10.1002/smi.2807. Epub 2018 Mar 30.

2.

Differential Associations Between Excess Body Weight and Psychiatric Disorders in Men and Women.

Husky MM, Mazure CM, Ruffault A, Flahault C, Kovess-Masfety V.

J Womens Health (Larchmt). 2018 Feb;27(2):183-190. doi: 10.1089/jwh.2016.6248. Epub 2017 Jul 7.

PMID:
28686068
3.

The effects of mindfulness training on weight-loss and health-related behaviours in adults with overweight and obesity: A systematic review and meta-analysis.

Ruffault A, Czernichow S, Hagger MS, Ferrand M, Erichot N, Carette C, Boujut E, Flahault C.

Obes Res Clin Pract. 2017 Sep - Oct;11(5 Suppl 1):90-111. doi: 10.1016/j.orcp.2016.09.002. Epub 2016 Sep 19. Review.

PMID:
27658995
4.

Randomized controlled trial of a 12-month computerized mindfulness-based intervention for obese patients with binge eating disorder: The MindOb study protocol.

Ruffault A, Carette C, Lurbe I Puerto K, Juge N, Beauchet A, Benoliel JJ, Lacorte JM, Fournier JF, Czernichow S, Flahault C.

Contemp Clin Trials. 2016 Jul;49:126-33. doi: 10.1016/j.cct.2016.06.012. Epub 2016 Jun 29.

PMID:
27370231
5.

Do karate fighters use situational probability information to improve decision-making performance during on-mat tasks?

Milazzo N, Farrow D, Ruffault A, Fournier JF.

J Sports Sci. 2016 Aug;34(16):1547-56. doi: 10.1080/02640414.2015.1122824. Epub 2015 Dec 14.

PMID:
26651505
6.

A Cognitive and Virtual Reality Treatment Program for the Fear of Flying.

Ferrand M, Ruffault A, Tytelman X, Flahault C, Négovanska V.

Aerosp Med Hum Perform. 2015 Aug;86(8):723-7. doi: 10.3357/AMHP.4211.2015.

PMID:
26387896
7.

Algorithm-based prediction of HIV-1 subtype D coreceptor use.

Dina J, Raymond S, Maillard A, Le Guillou-Guillemette H, Rodalec A, Beby-Defaux A, Giraudeau G, Vallet S, Mourez T, Payan C, Vabret A, Ruffault A, Ferre V, Izopet J, Plantier JC.

J Clin Microbiol. 2013 Sep;51(9):3087-9. doi: 10.1128/JCM.00798-13. Epub 2013 Jun 26.

8.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

Assoumou L, Descamps D, Yerly S, Dos Santos G, Marcelin AG, Delaugerre C, Morand-Joubert L, Ruffault A, Izopet J, Plantier JC, Pakianather S, Montes B, Chaix ML, Wirden M, Costagliola D, Masquelier B; ANRS AC11 Resistance Group.

J Antimicrob Chemother. 2013 Jun;68(6):1400-5. doi: 10.1093/jac/dkt033. Epub 2013 Feb 12.

PMID:
23404192
9.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. No abstract available.

PMID:
23184711
10.

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group.

Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886.

PMID:
22267476
11.

Human immunodeficiency virus infects human seminal vesicles in vitro and in vivo.

Deleage C, Moreau M, Rioux-Leclercq N, Ruffault A, Jégou B, Dejucq-Rainsford N.

Am J Pathol. 2011 Nov;179(5):2397-408. doi: 10.1016/j.ajpath.2011.08.005. Epub 2011 Sep 15.

12.

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.

13.

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9.

14.

Clinical pharmacology, efficacy and safety of atazanavir: a review.

Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E.

Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68. doi: 10.1517/17425250903321514. Review.

PMID:
19863454
15.

Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.

Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C; ANRS AC11 Working Group.

AIDS. 2009 Oct 23;23(16):2165-71. doi: 10.1097/QAD.0b013e32833032d4.

PMID:
19657270
16.

Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo.

Le Tortorec A, Satie AP, Denis H, Rioux-Leclercq N, Havard L, Ruffault A, Jégou B, Dejucq-Rainsford N.

Retrovirology. 2008 Dec 31;5:119. doi: 10.1186/1742-4690-5-119.

17.

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08. Epub 2008 Jul 14.

18.

Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation.

Le Tortorec A, Denis H, Satie AP, Patard JJ, Ruffault A, Jégou B, Dejucq-Rainsford N.

Hum Reprod. 2008 Sep;23(9):2095-103. doi: 10.1093/humrep/den207. Epub 2008 Jun 20.

19.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13.

PMID:
18552344
20.

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group.

J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4.

PMID:
18390885
21.

Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.

Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):12-8.

PMID:
17514016
22.

Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Gueudin M, Plantier JC, Lemée V, Schmitt MP, Chartier L, Bourlet T, Ruffault A, Damond F, Vray M, Simon F.

J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):500-5.

PMID:
17259908
23.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
24.

Multiple organ failure during primary HIV infection.

Tattevin P, Camus C, Arvieux C, Ruffault A, Michelet C.

Clin Infect Dis. 2007 Feb 1;44(3):e28-9. Epub 2007 Jan 2.

PMID:
17205433
25.

Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro.

Roulet V, Satie AP, Ruffault A, Le Tortorec A, Denis H, Guist'hau O, Patard JJ, Rioux-Leclerq N, Gicquel J, Jégou B, Dejucq-Rainsford N.

Am J Pathol. 2006 Dec;169(6):2094-103.

26.

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance.

Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D.

J Med Virol. 2006 Feb;78(2):153-60.

PMID:
16372300
27.

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.

Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V.

Antimicrob Agents Chemother. 2005 May;49(5):1720-6.

28.

French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.

Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Schmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vezinet F, Meyer L, Costagliola D.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):545-52.

PMID:
15793364
29.

HIV-1 group M superinfection in an HIV-1 group O-infected patient.

Plantier JC, Lemée V, Dorval I, Gueudin M, Braun J, Hutin P, Ruffault A, Simon F.

AIDS. 2004 Dec 3;18(18):2444-6. No abstract available.

PMID:
15622327
30.

Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group.

Antivir Ther. 2004 Jun;9(3):315-23.

PMID:
15259894
31.

Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.

Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, Pellegrin I, Izopet J, Ruffault A, Masquelier B, Meyer L, Rouzioux C, Brun-Vezinet F, Costagliola D.

AIDS. 2003 Dec 5;17(18):2635-43.

PMID:
14685058
32.

Production of the antiviral proteins 2'5'oligoadenylate synthetase, PKR and Mx in interstitial cells and spermatogonia.

Melaine N, Liénard MO, Guillaume E, Ruffault A, Dejucq-Rainsford N, Jégou B.

J Reprod Immunol. 2003 Jun;59(1):53-60.

PMID:
12892903
33.

Clinically relevant interpretation of genotype for resistance to abacavir.

Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D; Narval (ANRS 088) Study group.

AIDS. 2003 Aug 15;17(12):1795-802.

PMID:
12891065
34.

Experimental inoculation of the adult rat testis with Sendai virus: effect on testicular morphology and leukocyte population.

Melaine N, Ruffault A, Dejucq-Rainsford N, Jégou B.

Hum Reprod. 2003 Aug;18(8):1574-9.

PMID:
12871865
35.

Mumps virus decreases testosterone production and gamma interferon-induced protein 10 secretion by human leydig cells.

Le Goffic R, Mouchel T, Ruffault A, Patard JJ, Jégou B, Samson M.

J Virol. 2003 Mar;77(5):3297-300.

36.

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.

37.

Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

Arvieux C, Tattevin P, Souala FM, Jaccard P, Ruffault A, Bentué-Ferrer D, Tribut O, Chapplain JM, Dupont M, Bouvier C, Michelet C.

HIV Clin Trials. 2002 Mar-Apr;3(2):125-32.

PMID:
11976990
39.

Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.

Michelet C, Ruffault A, Sébille V, Arvieux C, Jaccard P, Raffi F, Bazin C, Chapplain JM, Chauvin JP, Dohin E, Cartier F, Bellissant E.

Antimicrob Agents Chemother. 2001 Dec;45(12):3393-402.

40.

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.

Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, Costagliola D; ANRS Antiretroviral Resistance Study Group.

AIDS. 2001 Sep 28;15(14):1777-82.

PMID:
11579238
41.

Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, Ruffault A, Mohammed AS, Cottalorda J, Schmuck A, Calvez V, Dam E, Fleury H, Brun-Vézinet F; ANRS AC11 Resistance study group. French Agence Nationale de Recherches sur le SIDA.

Antimicrob Agents Chemother. 2001 Jun;45(6):1836-42.

42.

HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.

Burgard M, Izopet J, Dumon B, Tamalet C, Descamps D, Ruffault A, Vabret A, Bargues G, Mouroux M, Pellegrin I, Ivanoff S, Guisthau O, Calvez V, Seigneurin JM, Rouzioux C.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):1939-47.

PMID:
11153076
43.

JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy.

Dubois V, Moret H, Lafon ME, Brodard V, Icart J, Ruffault A, Guist'hau O, Buffet-Janvresse C, Abbed K, Dussaix E, Ingrand D.

J Infect Dis. 2001 Jan 15;183(2):213-217. Epub 2000 Nov 29.

PMID:
11110646
44.

Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.

Masquelier B, Descamps D, Carrière I, Ferchal F, Collin G, Denayrolles M, Ruffault A, Chanzy B, Izopet J, Buffet-Janvresse C, Schmitt MP, Race E, Fleury HJ, Aboulker JP, Yeni P, Brun-Vézinet F.

Antivir Ther. 1999;4(2):69-77.

PMID:
10682151
45.

Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients.

Michelet C, Chapplain JM, Petsaris O, Arvieux C, Ruffault A, Lotteau V, André P.

AIDS. 1999 Oct 1;13(14):1995-6. No abstract available.

PMID:
10513670
46.

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.

Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.

Clin Pharmacol Ther. 1999 Jun;65(6):661-71.

PMID:
10391672
47.

[Beta interferon in multiple sclerosis: pharmacological differences].

Allain H, Bentué-Ferrer D, Schück S, Ruffault A.

Rev Neurol (Paris). 1999;155 Suppl 2:S24-30. Review. French.

PMID:
10367322
48.

Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study.

Dubois V, Moret H, Lafon ME, Janvresse CB, Dussaix E, Icart J, Karaterki A, Ruffault A, Taoufik Y, Vignoli C, Ingrand D.

J Neurovirol. 1998 Oct;4(5):539-44.

PMID:
9839651
49.

Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: relative balance between host immune response and the spread of HIV type 1 infection.

Bariou C, Genetet N, Ruffault A, Michelet C, Cartier F, Genetet B.

AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1301-12.

PMID:
9339847
50.

New types of primers (stair primers) for PCR amplification of the variable V3 region of the human immunodeficiency virus.

Colimon R, Minjolle S, André P, de la Pintière CT, Ruffault A, Michelet C, Cartier F.

J Virol Methods. 1996 Apr 26;58(1-2):7-19.

PMID:
8783146

Supplemental Content

Loading ...
Support Center